Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. An Indian pharmaceutical manufacturer has delayed commercial supplies of a recently launched diabetes therapy after identifying quality issues in certain production batches. The manufacturer is investigating the cause and implementing corrective measures, while confirming no impact on patient safety or existing regulatory filings.
Source: short-url.cc/1yS8o

2. India’s Rajasthan government has reportedly ordered the recall of Dinoprostone Gel, a labour-inducing medicine, after it failed quality testing. The state drug control department has directed the withdrawal of the affected batch and initiated regulatory action against the manufacturer. The recall reflects Rajasthan’s strengthened drug quality surveillance framework and is expected to increase regulatory scrutiny of pharmaceutical manufacturers supplying medicines under government procurement programmes.
Source: short-url.cc/1tkZK

3. India’s Ministry of Health and Family Welfare (MoHFW) has notified the amendment to the Drugs Rules, 1945, to designate Navi Mumbai as an additional port for the import of drugs under the prescribed regulatory framework. The amendment expands the list of notified ports for drug imports. The notification is expected to facilitate import operations, strengthen regulatory administration and improve logistical efficiency for pharmaceutical importers and other stakeholders engaged in the supply chain.
Source: short-url.cc/1tkZV

4. India’s Central Drugs Standard Control Organisation (CDSCO) has reportedly directed manufacturers to update the safety labels and prescribing information for several common antimicrobial drugs due to newly identified adverse reactions. The revised labels are intended to improve the safe use of these medicines by strengthening risk communication for healthcare professionals and patients, while reinforcing India’s pharmacovigilance and drug safety monitoring framework.
 Source: short-url.cc/1tk-1

5. India’s drug regulator, CDSCO, has reportedly proposed to bring mandatory registration for manufacturers and suppliers of pharmaceutical packaging materials and be governed under the Drugs Rules, 1945. A sub-committee will be set up to examine the necessity and feasibility for registered printing entities. Pharmaceutical packaging manufacturers are currently only indirectly regulated via drug manufacturers’ Schedule M vendor qualification systems, which regulators now deem inadequate to prevent misuse of genuine packaging.
Source: short-url.cc/1tk-6

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s Maharashtra’s Food and Drug Administration has reportedly issued a public warning against the use of three cosmetic products after laboratory testing detected excessive levels of mercury and lead, rendering them non-compliant with prescribed safety standards. The regulator has advised consumers to avoid using the affected products and has initiated appropriate regulatory action to prevent their sale and distribution. The move underscores the FDA’s continued efforts to safeguard public health by enforcing quality and safety standards for cosmetics.
Source: short-url.cc/1yGXL

2. Food Safety and Standards Authority of India has reportedly issued notices to energy drink brands for their misleading claims of “energy drink on product branding and labelling”. The FSSAI further states that the Food Category System under the Food Safety and Standards Regulations is not intended for product naming or labelling purposes.
Source: short-url.cc/1taa0

3. The Indian Pharmaceutical Association (IPA) has urged the ministry of health and family welfare (MoHFW) to remove AYUSH and Homeopathy provisions from the National Pharmacy Commission Bill, 2026. The association contended that the proposed bill should remain confined to the regulation of modern pharmacy education and practice, stating that the inclusion of traditional systems of medicine could dilute the existing regulatory framework for pharmaceutical sciences.
Source: short-url.cc/1yGXT

4. The Maharashtra Government has introduced the Maharashtra Clinical Establishments (Registration and Regulation) Bill, 2026, to create a comprehensive regulatory framework for clinical establishments. Replacing the Bombay Nursing Homes Registration Act, 1949, the Bill mandates registration, prescribes minimum standards, strengthens patient rights, promotes fee transparency and establishes oversight and enforcement mechanisms.
Source: short-url.cc/1taab

5. The Jharkhand High Court has held that bhang does not fall within the definition of “cannabis (hemp)” under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The Court observed that the statutory definition covers charas, ganja, and specified cannabis preparations, but does not include bhang prepared from cannabis leaves. Accordingly, the Court ruled that the possession or sale of bhang, by itself, does not attract the penal provisions of the NDPS Act, reaffirming the distinction drawn under the statutory framework.
Source: short-url.cc/1taah

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. A major food manufactured in the USA has removed all certified artificial colours from its food and beverage portfolio successfully, achieving its goal of fully eliminating them by the middle of this year. This move was announced in June 2025 and was confirmed that more than 90% of its U.S. portfolio was already free from synthetic dyes. These reformulated products have started arriving for consumption in the USA.
Source: short-url.cc/1xs6v

2. Hong Kong’s Department of Health has announced that medical gases will be regulated as pharmaceutical products from June 14, 2026, requiring manufacturers, wholesalers, and retailers to obtain relevant licences. Products containing nitrous oxide and nitric oxide will be classified as prescription medicines. Non-compliance may result in fines, imprisonment, and other regulatory enforcement actions.
Source: short-url.cc/1rZJs

3. The U.S. Food and Drug Administration (FDA) has issued warning letters to multiple entities for alleged violations of current Good Manufacturing Practice (CGMP) requirements and for the unlawful marketing of GLP-1 receptor agonist drugs through telehealth platforms. These warnings address firms that do not meet quality standards and telehealth providers promoting unapproved products for weight loss. The FDA emphasised compliance with manufacturing, quality, and marketing rules, and cautioned that failure to address the identified violations could result in further regulatory action.
Source: short-url.cc/1xs6F

4. India’s Central government has amended the marine export laws for export administration, effective from 9th June 2026. To modernize export administration, the notification mandates online registration workflows and establishes revised fee schedules. The legislative intent is to digitize statutory record-keeping and enforce strict compliance protocols governing ownership transfers, facility modifications, and dealer licensing across vessels, processing plants, and storage premises.
Source: short-url.cc/1rZJV

5. The World Health Organization has urged countries to shift from visual inspection and cytology-based screening to Human Papillomavirus testing for cervical cancer prevention. The updated recommendation highlights superior accuracy in detecting high-risk infections and supports wider adoption of affordable, locally developed Human Papillomavirus tests to accelerate cervical cancer elimination efforts.
Source: short-url.cc/1xs6P

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Employees’ State Insurance Corporation (ESIC) has launched a centralized online patient feedback system across its hospitals and dispensaries nationwide to strengthen patient-centric healthcare delivery. The digital platform enables beneficiaries to submit feedback on healthcare services received at ESIC facilities, facilitating real-time monitoring of patient experiences and service quality. The initiative will help identify service gaps, support continuous quality improvement, and strengthen the overall healthcare experience for insured persons and their dependents.
Source: shortlink.uk/1rjWU

2. The Himachal Pradesh High Court has quashed criminal proceedings against a liquor manufacturer arising from the transport of liquor consignments where authorities found two liquor cases without a valid permit and bottles bearing batch numbers different from those specified in the permit. The Court observed that the batch-number discrepancies resulted from inadvertent labelling errors by workers, with no evidence of adulteration or revenue loss to the government. Holding that only the transport of the two unpermitted liquor cases constituted an offence, the Court compounded the matter and imposed a monetary penalty, while allowing separate departmental action for licence-condition violations to continue.
Source: shortlink.uk/1wKXJ

3. The Ministry of Health and Family Welfare has notified an amendment to Schedule V of the Drugs Rules, 1945, substituting the unit for folic acid from “mg” (milligram) to “mcg” (microgram). The amendment will come into force six months from the date of its publication in the Official Gazette.
Source: shortlink.uk/1rjX4

4. The Ministry of AYUSH has amended the NCISM appointment rules to reduce the minimum experience required for appointment as Secretary to the Commission from 15 years to 7 years. The amendments also clarify that serving government officials appointed to NCISM or its Autonomous Boards will be treated as being on deputation and provide alternative provident fund coverage where General Provident Fund subscription is unavailable. This strengthens the institutional and human-resource framework of the NCISM, which oversees standards in Indian systems of medicine.
Source: shortlink.uk/1rjWU

5. The National Pharmaceutical Pricing Authority (NPPA) is considering raising prices of key platinum-based cancer drugs like cisplatin and carboplatin after manufacturers flagged steep increases in raw material costs, especially platinum. Authorities are balancing concerns over patient affordability with the risk of supply shortages if prices remain unchanged.
Source: shortlink.uk/1wKXQ

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s Supreme Court has held that access to trauma care is a fundamental right under Article 21, directing all States and UTs to unify emergency helplines under 112, establish trauma registries, operationalise cashless treatment for road accident victims, and enforce ambulance tracking standards within set timelines. The ruling significantly expands constitutional obligations on healthcare infrastructure, emergency services, insurers, and public health governance across India. It also needs to have physical and digital grievance redressal systems for good samaritans. This classification is not restricted to national highways but extends to state highways and district roads too.
Source: shortlink.uk/1qB9n

2. The government has reportedly referred 27 doctors to the National Medical Commission (NMC) for disciplinary action in connection with a pharmaceutical freebies case involving sponsored foreign trips under the guise of rendering of knowledge dissemination service. The matter relates to alleged acceptance of luxury travel and hospitality benefits linked to pharmaceutical promotional activities, with State Medical Councils now expected to examine the cases pursuant to violation of MCI Code of Ethics. The development intensifies scrutiny around pharma-doctor engagement practices, and enforcement of professional conduct regulations within the healthcare sector.
Source: shortlink.uk/1vZFF

3. The Central Consumer Protection Authority (CCPA) initiated regulatory action against unauthorized online sale of hazardous chemicals like ammonium nitrate, PETN, gun powder, and picric acid. Notices were issued to e-commerce platforms, seller details shared with PESO, and platforms began delisting products to ensure consumer safety and compliance
Source: shortlink.uk/1vZFK

4. Pharmaceutical manufacturers are increasingly focusing on contamination control infrastructure, particularly Air Handling Unit (AHU) filter maintenance systems, to support compliance with revised Schedule M requirements. Industry experts note that heightened regulatory expectations around hygiene, traceability, cross-contamination prevention, and cleanroom maintenance are driving interest in automated AHU filter cleaning and maintenance technologies.
Source: shortlink.uk/1vZFU

5. Government of India is reportedly planning to launch a dedicated childhood cancer registry which aims to systematically collect data on cancer cases in children in collaboration with the Indian Council of Medical Research (ICMR). India records around seventy-five thousand new cancer cases annually, many detected late. The government plans awareness, data collection, and collaborations to improve early diagnosis and treatment outcomes.
Source: shortlink.uk/1qB8R

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Reader, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Doctors can sell medicines to their patients without obtaining a separate license for selling drugs after complying with all the conditions specified under the Drugs Rules, 1945: Bombay High Court
Source: bit.ly/4cqy94s

2. Drugs which are approved in USA, UK, Japan, Australia, Canada and EU have been exempt from requirement to conduct clinical trials in India before securing a marketing approval, if they fall into the categories of Orphan Drugs for Rare Diseases, Gene and Cellular Therapy Products, New Drugs used in Pandemic Situations, New Drugs for Special Defense Purposes, and New Drugs that represent a significant therapeutic advance.
Source: bit.ly/4cmWZ4W

3. India’s Central Drug Regulator (CDSCO) has made it mandatory to follow WHO Technical Report Series (TRS) guidelines in so far as they relate to Good Manufacturing Practices, such as the “WHO Good Manufacturing Practices for Sterile Pharmaceutical Products.”
Source: bit.ly/3yyC4y6

4. India’s Central Government is reportedly planning to introduce a separate marketing practices code for medical devices. The proposed code aims to establish a voluntary framework to regulate marketing practices within the medical devices industry.
Source: bit.ly/4dvF6BY

5. Indian Government has revised hazardous residue standards for fruits and vegetables meant for domestic consumption and introduced new hazardous residue standards for fruits and vegetables meant for export purposes. Fruits and vegetables meant for export should comply with standards set by the Codex Alimentarius Commission or the importing country’s requirements.
Source: bit.ly/4fDKLYM